Efficacy of an Oral Ageratum Conyzoides Formulation on Increasing Hair Growth and Decreasing Hair Loss in Males and Females: A Randomised Double-Blind Placebo-Controlled Study
DOI:
https://doi.org/10.17140/TCOJ-6-119Keywords:
Ageratum conyzoides, Hair growth, Hair loss, Androgenetic alopecia, Oral supplementationAbstract
Background
Androgenetic alopecia (AGA) is associated with the enzyme 5a-reductase and prostaglandin D2, both of which are increased in bald areas of the scalp. We previously demonstrated the safety and efficacy of a topical Ageratum conyzoides (A. conyzoides) formulation in improving hair growth and decreasing hair loss.
Objective
A follow-up 12-week double-blind, randomised clinical trial investigating the efficacy and safety of A. conyzoides extract in an oral formulation, in males and females over 18-years of age.
Methods
250 mg of A. conyzoides or a placebo was supplemented daily over a 12-week period to 84 healthy males or females with hair loss. The primary outcome was hair growth assessed by measuring hair density using HairCheck®, and hairline recession. Hair loss was measured by the mean number of hairs lost in a one-minute combing test and hair/tug pull test. Other assessments included Norwood/Hamilton and Ludwig-Savin scales evaluating male and female pattern baldness, respectively. Biochemical and haematological parameters were also assessed, as change from baseline for each group.
Results
Twelve (12)-week daily supplementation of A. conyzoides resulted in a significant reduction in hairline recession compared to the placebo group. A trend towards significance was observed for hair density between groups, where hair density increased in the A. conyzoides group and decreased in placebo group from their respective baseline values. No significant differences were found in hair loss measures or the Norwood/Hamilton and Ludwig-Savin scales. A significant difference was found in the change from baseline for total prostaglandins between groups at week 12, with a decrease from baseline in the active group and an increase in the placebo group. In males, a significant difference in the change from baseline was seen for type-2 5a-reductase, with a decrease from baseline in the active group and increase in the placebo group.
Conclusion
These results demonstrate an improvement in hair growth following the 12-week oral supplementation of A. conyzoides extract., with mechanistic convergence.
References
Ho CH, Sood T, Zito PM. Androgenetic Alopecia. FL, USA: Stat-Pearls Publishing; 2023.
Magro CM, Rossi A, Poe J, Manhas-Bhutani S, Sadick N. The role of inflammation and immunity in the pathogenesis of andro-genetic alopecia. J Drugs Dermatol. 2011; 10(12): 1404-1411.
Clayton P. Are alopecias non-communicable degenerative dis-eases? Hair Ther Transplant. 2022; 12(3): 1-6. doi: 10.35248/2167- 0951.22.12.192
Trueb RM. Molecular mechanisms of androgenetic alope-cia. Exp Gerontol. 2002; 37(8-9): 981-990. doi: 10.1016/s0531- 5565(02)00093-1
Garza LA, Liu Y, Yang Z, et al. Prostaglandin D2 inhibits hair growth and is elevated in bald scalp of men with androgenetic alopecia. Sci Transl Med. 2012; 4(126): 126ra34. doi: 10.1126/sci-translmed.3003122
Cash TF. The psychology of hair loss and its implications for pa-tient care. Clin Dermatol. 2001; 19(2): 161-166. doi: 10.1016/s0738- 081x(00)00127-9
Wall D, Meah N, Fagan N, York K, Sinclair R. Advances in hair growth. Fac Rev. 2022; 11: 1. doi: 10.12703/r/11-1
Rittmaster RS. Finasteride. N Engl J Med. 1994; 330(2): 120-125. doi: 10.1056/NEJM199401133300208
Messenger AG, Rundegren J. Minoxidil: Mechanisms of ac-tion on hair growth. Br J Dermatol. 2004; 150(2): 186-194. doi:
1111/j.1365-2133.2004.05785.x 10. Rossi A, Campo D, Fortuna MC, et al. A preliminary study on topical cetirizine in the therapeutic management of andro-genetic alopecia. J Dermatolog Treat. 2018; 29(2): 149-151. doi: 10.1080/09546634.2017.1341610
Evron E, Juhasz M, Babadjouni A, Mesinkovska NA. Natural Hair Supplement: Friend or foe? Saw palmetto, a systematic re-view in alopecia. Skin Appendage Disord. 2020; 6(6): 329-337. doi: 10.1159/000509905
Okunade AL. Ageratum conyzoides L. (Asteraceae). Fitoterapia. 2002; 73(1): 1-16. doi: 10.1016/s0367-326x(01)00364-1
Kaur R, Dogra NK. A review on traditional uses, chemical constituents and pharmacology of Ageratum conyzoides L. (As-teraceae). Int J Pharm Biol. 2014; 5: 33-45.
Clayton P, Venkatesh R, Bogoda N, Subah S. Ageratum conyzoides L. extract inhibits 5α-reductase gene expression and prostaglandin D2 release in human hair dermal papilla cells and improves symptoms of hair loss in otherwise healthy males and females in an open label pilot study. J Cosmet Trich. 2021; 7(1): 1-7.
Clayton P, Venkatesh R, Shama, Bogoda N, Subah S, Rao A. Efficacy of a topical application of ageratum conyzoides on in-creasing hair growth and in males and females: A randomized dou-ble-blind placebo-controlled study. Journal of Cosmetology & Trichol-ogy. 2022; 8(3): 1-5. doi: 10.37421/2471-9323.2022.8.179
Palmer PA, Bryson JA, Clewell AE, et al. A comprehensive tox-icological safety assessment of an extract of Ageratum conyzoi-Submit your article to this journal | https://openventio.org/submit-manuscript/ des. Regul Toxicol Pharmacol. 2019; 103: 140-149. doi: 10.1016/j. yrtph.2019.01.027
Subah S, Bogoda N, Glavits R, Venkatesh R, Murbach TS, Ko-lep-Csete K. Prenatal developmental toxicity study of an alkaloid-free Ageratum conyzoides extract powder in rats by oral adminis-tration. Regul Toxicol Pharmacol. 2020; 117: 104748. doi: 10.1016/j. yrtph.2020.104748
Wikramanayake TC, Mauro LM, Tabas IA, Chen AL, Llanes IC, Jimenez JJ. Cross-section trichometry: A clinical tool for as-sessing the progression and treatment response of alopecia. Int J Trichology. 2012; 4(4): 259-264. doi: 10.4103/0974-7753.111221
Detering M, Steels E, Koyyalamudi SR, Allifranchini E, Boc-chietto E, Vitetta L. Ageratum conyzoides L. inhibits 5-alpha-re-ductase gene expression in human prostate cells and reduces symp-toms of benign prostatic hypertrophy in otherwise healthy men in a double blind randomized placebo controlled clinical study. Biofac-tors. 2017; 43(6): 789-800. doi: 10.1002/biof.1389
Faqueti LG, Brieudes V, Halabalaki M, et al. Antinociceptive and anti-inflammatory activities of standardized extract of poly-methoxyflavones from Ageratum conyzoides. J Ethnopharmacol. 2016; 194: 369-377. doi: 10.1016/j.jep.2016.09.025
Published
How to Cite
Issue
Section
License

This work is licensed under a Creative Commons Attribution 4.0 International License.
All content published in Trichology and Cosmetology (TC) is licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This license allows anyone to copy, distribute, transmit, and adapt the work — including for commercial purposes — provided appropriate credit is given to the original author(s) and source.